c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. - Bellon,S.; Kaplan-Lefko,P.; Yang,Y.; Zhang,Y.; Moriguchi,J.; Rex,K.; Johnson,C.; Rose,P.; Long,A.; O'Connor,A.; Gu,Y.; Coxon,A.; et al. (J Biol Chem, 2008)